Bluemtec is a pharmaceutical distribution company founded in 2015, operating Bluefarm Korea, a B2B pharmaceutical e-commerce platform for clinics. It also runs a pharmacy-facing service and Bluedoc, a job platform for medical professionals.
According to the company, the platform had more than 36,200 members at the end of 2025, and 25,328 of the 37,514 clinic-level medical institutions nationwide (67.5%) had joined. The product mix is widening toward GLP-1 drugs, osteoporosis treatments and vaccines.
In aesthetics, the company distributes Medytox botulinum toxin products online and signed a filler and skin booster distribution agreement with Bioplus, disclosed on April 29, 2026.
The company attributed 2025 revenue growth mainly to demand for obesity drugs such as Wegovy and Mounjaro and to higher purchase volumes per loyal customer under its membership benefits.
In vaccines, the switch in the national flu vaccine from quadrivalent to trivalent created a supply-demand mismatch that led to KRW 1.8 billion in vaccine disposal losses in 2025. The company is reducing its flu vaccine share and expanding AI inventory management and personalized drug recommendations.
Its logistics rely on about 100 vehicles equipped with cold-chain systems. The company cites its clinic customer base and purchasing data as the basis of its platform competitiveness.